Cite
HARVARD Citation
Robson, M. et al. (2019). Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. European journal of cancer. pp. 20-30. [Online].